Aberrant expression of tissue transglutaminase in ovarian tumors has been implicated as an upstream regulator of p52 expression and non-canonical signaling, ultimately contributing to disease progression and intraperitoneal metastasis [31]. Here, TGM2 is linked to ovarian neoplasm.